MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/640/0.01/20.12.24 | Market Closed - Börse Stuttgart 09:51:14 28/05/2024 BST | ||
| 0.076 EUR | +7.04% |
|
| 1 month | +16.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/05/24 | 0.076 | +7.04% |
| 27/05/24 | 0.071 | -1.39% |
| 24/05/24 | 0.072 | +1.41% |
| 23/05/24 | 0.071 | +1.43% |
| 22/05/24 | 0.07 | +4.48% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 09:51 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG29XF |
| ISIN | DE000MG29XF7 |
| Date issued | 12/04/2024 |
| Strike | 640 $ |
| Maturity | 20/12/2024 (206 Days) |
| Parity | 100 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.076 € |
|---|---|
| Lowest since issue | 0.051 € |
| Spread | 0.01 € |
| Spread % | 12.05% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
